Coherus Oncology (CHRS) Net Margin (2013 - 2026)

Coherus Oncology has disclosed Net Margin across 13 years of filings, most recently posting 11.31% for Q1 2026.

• Net Margin for Q1 2026 came in at 11.31%, up 10938.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 765.58% (up 56039.0% YoY), and the FY2025 annual result was 832.66%, down 9160.0% from the prior year.
• Net Margin came in at 11.31% for Q1 2026 at Coherus Oncology, down from 68.28% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 7405.16% in Q1 2024 to a low of 233.47% in Q1 2023.
• The 5-year median for Net Margin is 59.52% (2024), against an average of 629.8%.
• Across the five-year window, Net Margin soared 763863 bps in 2024 and sank 752584 bps in 2025, its largest moves.
• Coherus Oncology's Net Margin stood at 129.81% in 2022, then soared by 33 bps to 87.03% in 2023, then jumped by 32 bps to 59.52% in 2024, then soared by 215 bps to 68.28% in 2025, then slumped by 117 bps to 11.31% in 2026.
• The last three Net Margin figures came in at 11.31% (Q1 2026), 68.28% (Q4 2025), and 77.66% (Q3 2025), per Business Quant data.